Evidence map›Paper›PMID 30657463›Full record

ArticleSexually transmitted diseases2019

Is It Time to Stop Using Single-dose Oral Metronidazole for the Treatment of Trichomoniasis in Women?

Christina A Muzny, Saralyn Richter, Patricia Kissinger

Open access · greenAbstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Sexually transmitted diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Secnidazole: a treatment for trichomoniasis in adolescents and adults.Expert review of anti-infective therapy · 2022
    Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Christina A Muzny
Saralyn Richter
Patricia KissingerDepartment of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA.
University of Alabama at Birmingham · USTulane University · US

Funding

Tracking & Evaluation CoreU54GM104940 · NIGMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI Leigh Lamonica · 2012 to 2026
$69.1M
Trichomonas vaginalis repeat infections among HIV negative womenR01AI097080 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI KISSINGER, PATRICIA J · 2012 to 2016
$3.7M
A new approach to controlling chlamydia transmission in young peopleR01HD086794 · NICHD · TULANE UNIVERSITY OF LOUISIANA · PI KISSINGER, PATRICIA J · 2016 to 2020
$2.9M
Pathogenesis of Bacterial Vaginosis in Women Who Have Sex with WomenK23AI106957 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MUZNY, CHRISTINA A · 2014 to 2018
$873k
NIAID NIH HHS K23 AI106957NIAID NIH HHS R01 AI097080NICHD NIH HHS R01 HD086794NIGMS NIH HHS U54 GM104940
6 · The paper itself

Abstract

The 2015 Centers for Disease Control Sexually Transmitted Disease treatment guidelines currently recommend a single 2-g dose of oral metronidazole as the preferred regimen for treatment of trichomoniasis in human immunodeficiency virus (HIV)-negative women. Mounting recent evidence has shown that the 7-day oral metronidazole dosing regimen is more efficacious than the single 2-g dose. This commentary reviews the implications associated with these new data and discusses issues surrounding it that should be considered moving forward.

Indexed as

Drug Administration ScheduleAdministration, OralClinical Trials as TopicFemaleHumansMetronidazoleSexually Transmitted DiseasesTrichomonas InfectionsMetronidazole

Identifiers

PMID30657463
PMCPMC6465136
OpenAlexW2902018444

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.